6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carbonitrile | 123044-16-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carbonitrile
• 英文别名: 6-methyl-2-oxo-4-phenyl-3,4-dihydro-1H-pyrimidine-5-carbonitrile
• CAS: 123044-16-6
• 化学式: C₁₂H₁₁N₃O
• 分子量: 213.239
• InChiKey: GWHSEBBRMCQXQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  64.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carbonitrile 在 palladium on activated charcoal 作用下， 以 二苯醚 为溶剂， 反应 2.0h， 以81%的产率得到6-methyl-2-oxo-4-phenyl-1,2-dihydropyrimidine-5-carbonitrile
  参考文献：
  名称：

  Kappe, Christian Oliver; Roschger, Peter, Journal of Heterocyclic Chemistry, 1989, vol. 26, p. 55 - 64

  摘要：

  DOI：
• 作为产物：
  描述：

  4-methyl-2-oxo-6-phenyl-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid amide 在 甲烷磺酸 、 四磷十氧化物 作用下， 反应 0.5h， 以73%的产率得到6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carbonitrile
  参考文献：
  名称：

  Kappe, Christian Oliver; Roschger, Peter, Journal of Heterocyclic Chemistry, 1989, vol. 26, p. 55 - 64

  摘要：

  DOI：

文献信息

• Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
  申请人：——

  公开号：US20020143026A1

  公开（公告）日：2002-10-03

  The present invention provides compounds of formula I 1 and pharmaceutically acceptable salts thereof. The formula I compounds induce mitotic arrest thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inducing mitotic arrest.

  本发明提供了I式化合物及其药用可接受的盐。公式I化合物诱导有丝分裂停滞，因此使它们可用作抗癌剂。公式I化合物还可用于治疗其他可以通过诱导有丝分裂停滞来治疗的疾病。
• [EN] CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES<br/>[FR] COMPOSES DE DIHYDROPYRIMIDINE CYANO-SUBSTITUES ET LEUR UTILISATION POUR TRAITER DES MALADIES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2002079169A1

  公开（公告）日：2002-10-10

  The present invention provides compounds of formula (I), formula (I) and pharmaceutically acceptable salts thereof. The formula I compounds induce mitotic arrest thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inducing mitotic arrest.

  本发明提供了式(I)的化合物，式(I)和其药学上可接受的盐。式(I)化合物能够诱导有丝分裂停滞，因此它们可用作抗癌剂。式(I)化合物还可用于治疗其他可以通过诱导有丝分裂停滞来治疗的疾病。
• Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
  申请人：——

  公开号：US20030008888A1

  公开（公告）日：2003-01-09

  The present invention provides compounds of formula I 1 and pharmaceutically acceptable salts thereof. The formula I compounds induce mitotic arrest thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inducing mitotic arrest.

  本发明提供了I1式化合物及其药学上可接受的盐。I式化合物诱导有丝分裂停滞，因此它们可用作抗癌剂。I式化合物还可用于治疗其他可以通过诱导有丝分裂停滞来治疗的疾病。
• Separation of enantiomers of 4-aryldihydropyrimidines by direct enantioselective HPLC. A critical comparison of chiral stationary phases
  作者：Oliver P. Kleidernigg、C.Oliver Kappe

  DOI：10.1016/s0957-4166(97)00214-0

  日期：1997.6

  The separation of the enantiomers of 29 racemic 4-aryldihydropyrimidine-5-carboxylates (DHPMs), aza-analogs of nifedipine-type dihydropyridine calcium channel modulators, was evaluated in direct enantioselective HPLC, employing the following commercially available chiral stationary phases (CSPs): Chiralcel OD-H, ChiraDex, Chirobiotic V and T, and Whelk-O1. In addition, a 1,2-diphenyl-1,2-diaminoethane based CSP and two quinine carbamate based chiral ion exchangers were also employed. For all 29 DHPMs separation of individual enantiomers could be achieved with at least one CSP with alpha-values ranging from 1.10 to 8.67. (C) 1997 Elsevier Science Ltd.
• Gold Catalyzed Cyclization of Alkyne-Tethered Dihydropyrimidones
  作者：Lauren E. Brown、Peng Dai、John A. Porco、Scott E. Schaus

  DOI：10.1021/ol2015658

  日期：2011.8.19

  Dihydropyrimidones are an important class of biologically active heterocycles accessible from the multicomponent Biginelli condensation. Further manipulation of the dihydropyrimidone skeleton gives access to unique heterocycles. Presented herein is a Au-catalyzed cyclization of alkyne-tethered dihydropyrimidones to yield pyridopyrimidones.